Clinical trials: Ritonavir
Hepatic Insufficiency
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
To determine the pharmacokinetics of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) 500/200 mg in subjects with mild to moderate hepatic insufficiency
- Trial name
- NCT02249442
- Testing
- Tipranavir (TPV), Ritonavir (r)
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants
The purpose of this study is to evaluate effect of single and repeated doses of darunavir (DRV) in combination with cobicistat (DRV/COBI) and with ritonavir (DRV+rtv) on the pharmacokinetics of single dose dabigatran etexilate…
- Trial name
- NCT04208061
- Testing
- Dabigatran Etexilate, DRV/COBI, Ritonavir
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
HIV Infection
Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor
The Study will help to compare the Quality of Life for those HIV patients that are on monotherapy with LPV/r Vs. triple therapy with a boosted protease inhibitor
- Trial name
- QoLKAMON (NCT01166477)
- Testing
- Lopinavir and ritonavir, Triple therapy with ritonavir
- Where
- 31 sites in Spain
- Volunteers
- 228 people
- Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
HIV
A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
In the well recognized context of HIV infection chronicity, it is now crucial to identify and evaluate effective, well tolerated and affordable second line regimen in resources limited countries where patients often change…
- Trial name
- ALISA (NCT01255371)
- Testing
- Lopinavir, Atazanavir
- Where
- 2 sites in South Africa, Tanzania
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV
Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation
A phase I/II, open label, randomized crossover pharmacokinetic, safety and acceptability study of the Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination vs.
- Trial name
- LOLIPOP (NCT03836833)
- Testing
- ABC/3TC/LPV/r granules (30/15/40/10 mgs), LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)
- Where
- 3 sites in Uganda
- Volunteers
- 50 people
- Sponsor
- Drugs for Neglected Diseases
HIV Infection, Endothelial Dysfunction
RAltegravir Switch STudy: Effects on Endothelial Recovery
Treatment with HIV-infection with protease inhibitors is associated with high blood lipids and higher chance for cardiovascular complications.
- Trial name
- RASSTER (NCT01453933)
- Testing
- raltegravir
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- UMC Utrecht
Pneumonia Caused by Human Coronavirus (Disorder)
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection
The aim of this study is to test whether Traditional Chinese Medicines (TCMs) are effective and safe for treating COVID-19 infection.
- Trial name
- NCT04251871
- Testing
- Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules, Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Beijing 302 Hospital
HIV Infections
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy.
- Trial name
- NCT00619944
- Testing
- Lumefantrine - lopinavir/ritonavir drug interaction, Lumefantrine only arm
- Where
- Uganda
- Volunteers
- 32 people
- Sponsor
- Makerere University
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
HIV-1 Infection
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of…
- Trial name
- NCT02652624
- Testing
- E/C/F/TAF, E/C/F/TDF, ATV
- Where
- 56 sites in United States, Dominican Republic and 4 more
- Volunteers
- 472 people
- Sponsor
- Gilead Sciences
COVID, Pneumonia
Baricitinib Therapy in COVID-19
Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
- Trial name
- NCT04358614
- Testing
- Baricitinib 4 MG Oral Tablet
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Fabrizio Cantini
Healthy Volunteer
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants
This study is a single-center, double-blind, randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study that will evaluate the safety, tolerability and pharmacokinetics (PK) of RO6889678…
- Trial name
- NCT02321384
- Testing
- RO6889678, Midazolam, Ritonavir
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
HIV Infections
The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients
Treatment with only protease inhibitors might benefit HIV patients. Laboratory data have shown that the combination of saquinavir with lopinavir and ritonavir may a good regimen. This study will explore this idea.
- Trial name
- NCT00400738
- Testing
- Saquinavir, lopinavir, ritonavir
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Corona Virus Infection
Trial of Treatments for COVID-19 in Hospitalized Adults
DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the…
- Trial name
- DisCoVeRy (NCT04315948)
- Testing
- Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A
- Where
- 62 sites in Austria, Belgium and 5 more
- Volunteers
- 1,552 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
HIV Infections
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
The purpose of this study is to see if the amount of stem cells (cells that can develop into many kinds of cells) in the blood before anti-HIV drugs are taken can predict if the immune system will become stronger after anti-HIV…
- Trial name
- NCT00006578
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-2 Infection
RESIST-2: 2nd-line ART for HIV-2 Infection
Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.
- Trial name
- RESIST-2 (NCT03394196)
- Testing
- HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- Where
- 2 sites in Senegal
- Volunteers
- 152 people
- Sponsor
- University of Washington
HIV Infections, Tuberculosis
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
Rifampin (RIF) is used for the treatment of tuberculosis (TB), an infectious disease that affects many people with HIV. RIF was shown to lower concentrations and decrease the effectiveness of some anti-HIV drugs, including the…
- Trial name
- NCT00096850
- Testing
- Atazanavir, Rifampin, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Infection, Human Immunodeficiency Virus
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and…
- Trial name
- NCT00085943
- Testing
- LEXIVA (GW433908), Ritonavir, KALETRA
- Where
- 119 sites in United States, Austria and 12 more
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
This Phase Ⅱ/Ⅲ study is to evaluate whether or not there is a difference in time recovery of COVID-19 signs and symptoms through Day 29 between SIM0417/ritonavir and placebo.
- Trial name
- NCT05506176
- Testing
- SIM0417
- Where
- 35 sites in China
- Volunteers
- 1,208 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.